地塞米松与动脉瘤性蛛网膜下腔出血患者分流需求、早期残疾及内科并发症的关系
该回顾性研究纳入206例动脉瘤性蛛网膜下腔出血患者,按地塞米松方案分为无皮质激素组、短疗程组(4 mg每6小时1天,随后每日总剂量递减25%,最后一天递减50%)和长疗程组(4 mg每6小时5-7天,随后隔日减半)。三组在脑室外引流率(p=0.164)、脑室腹腔分流率(p=0.792)及出院时良好功能结局(mRS 0-3,p=0.928)方面均无差异。长疗程地塞米松组并发症发生率显著高于无皮质激素或短疗程组(78.4% vs. 58.6%;p=0.005),校正后长疗程地塞米松仍与合并不良事件风险升高独立相关(OR=2.72;95%CI 1.30-5.72;p=0.008),并与感染(OR=3.45;95%CI 1.63-7.30;p=0.001)和高血糖(OR=2.05;95%CI 1.04-4.04;p=0.039)风险升高独立相关。
要点
- 在206例aSAH患者中,无皮质激素、短疗程地塞米松和长疗程地塞米松三组的脑室外引流率(p=0.164)和脑室腹腔分流率(p=0.792)均无差异。
- 三组出院时良好功能结局(mRS 0-3)无差异(p=0.928),脑室外引流中位治疗时长(p=0.905)及拔管概率(log-rank p=0.256)亦无差异。
- 长疗程地塞米松组并发症发生率显著高于无皮质激素或短疗程组(78.4% vs. 58.6%;p=0.005)。
- 校正后长疗程地塞米松仍与合并不良事件风险升高独立相关(OR=2.72;95%CI 1.30-5.72;p=0.008),并与感染(OR=3.45;95%CI 1.63-7.30;p=0.001)和高血糖(OR=2.05;95%CI 1.04-4.04;p=0.039)风险升高独立相关。
适用人群与场景
- 动脉瘤性蛛网膜下腔出血(aSAH)患者,共206例,按地塞米松治疗方案分为无皮质激素组、短疗程地塞米松组和长疗程地塞米松组。
处置流程与药物剂量
- 短疗程地塞米松方案:4 mg每6小时用1天,随后每日总剂量递减25%,最后一天递减50%。
- 长疗程地塞米松方案:4 mg每6小时用5-7天,随后隔日减半。
研究设计与关键结果
- 研究类型为回顾性分析,纳入206例aSAH患者,按地塞米松方案分为无皮质激素组、短疗程地塞米松组和长疗程地塞米松组。
- 主要终点脑室腹腔分流置入率三组间无差异(p=0.792);脑室外引流率亦无差异(p=0.164)。
- 次要终点出院时良好功能结局(mRS 0-3)三组间无差异(p=0.928);脑室外引流中位治疗时长无差异(p=0.905),拔管概率相似(log-rank p=0.256)。
- 长疗程地塞米松组并发症发生率显著高于无皮质激素或短疗程组(78.4% vs. 58.6%;p=0.005)。
- 校正后长疗程地塞米松仍与合并不良事件风险升高独立相关(OR=2.72;95%CI 1.30-5.72;p=0.008),并与感染(OR=3.45;95%CI 1.63-7.30;p=0.001)和高血糖(OR=2.05;95%CI 1.04-4.04;p=0.039)风险升高独立相关。
证据类型、等级与局限
- 证据类型:回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于aSAH患者,地塞米松使用与脑室外引流及脑室腹腔分流置入率、脑室外引流治疗时长及出院时功能残疾无关。
- 长疗程地塞米松与内科并发症风险升高独立相关,包括合并不良事件、感染和高血糖。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Current guidelines do not support the routine use of corticosteroids in patients with aneurysmal subarachnoid hemorrhage (aSAH). However, corticosteroids use in aSAH has been practiced at some centers by convention. The aim of the study was to determine the incidence of hydrocephalus requiring ventriculoperitoneal shunt (VPS) placement as well as functional outcome on discharge and adverse events attributed to corticosteroids in patients with aSAH treated with different dexamethasone (DXM) treatment schemes.
METHODS: We retrospectively analyzed 206 patients with aSAH stratified to three groups based on the DXM treatment scheme: no corticosteroids, short course of DXM (S-DXM; 4 mg every 6 h for 1 day followed by a daily total dose reduction by 25% and then by 50% on last day), and long course of DXM (L-DXM; 4 mg every 6 h for 5-7 days followed by reduction by 50% every other day). The primary outcome measure was the placement of a VPS, and the secondary outcome was a good functional outcome [modified Rankin Scale (mRS) 0-3] at hospital discharge. Safety measures were the incidence of infection (pneumonia, urinary tract infection, ventriculitis, meningitis), presence of delirium, and hyperglycemia.
RESULTS: There was no difference in the rate of external ventricular drain (EVD) (p = 0.164) and VPS placement (p = 0.792), nor in the rate of good outcome (p = 0.928) among three defined treatment regimens. Moreover, the median duration of treatment with EVD did not differ between subjects treated with no corticosteroids, S-DXM, and L-DXM (p = 0.905), and the probability of EVD removal was similar when stratified according to treatment regimens (log-rank; p = 0.256). Patients who received L-DXM had significantly more complications as compared to patients, who received no corticosteroids or S-DXM (78.4% vs. 58.6%; p = 0.005). After adjustment, L-DXM remained independently associated with increased risk of combined adverse events (OR = 2.72; 95%CI, 1.30-5.72; p = 0.008), infection (OR = 3.45; 95%CI, 1.63-7.30; p = 0.001) and hyperglycemia (OR = 2.05; 95%CI, 1.04-4.04; p = 0.039).
CONCLUSIONS: DXM use among patients with aSAH did not relate to the rate of EVD and VPS placement, duration of EVD treatment, and functional disability at discharge but increased the risk of medical complications.
参考来源
- Miller MM, Dakay K, Henninger N, et al. Association of Dexamethasone with Shunt Requirement, Early Disability, and Medical Complications in Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care. 2020. PMID: 32851604. doi:10.1007/s12028-020-01059-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。